Lyophilized Peptide Stability: How Dry Peptides Degrade
Research peptides are usually supplied as a lyophilized (freeze-dried) powder, because a dry solid keeps far better than a solution. But "dry" doesn't mean "inert": chemical reactions still happen in the solid state, only more slowly. This guide explains which reactions those are, what speeds them up, and what that means for handling a sealed vial of powder. It covers the dry powder only.
Why peptides are freeze-dried
Proteins and peptides have limited stability in solution, so they are often made into solids to reach an acceptable shelf life. Lyophilization is the most commonly used way to do it (Wang, 2000). Freeze-drying is not free of stress, though: freezing and drying can themselves damage sensitive molecules, and even a well-made solid can still have limited long-term storage stability (Wang, 2000).
What still happens in the dry state
A review of solid-state chemical stability lists the major reactions that affect peptides and proteins even as solids (Lai & Topp, 1999):
- Deamidation. Asparagine residues can lose their side-chain amide through a cyclic imide intermediate, and aspartate residues can isomerize by a similar route. How reactive a given residue is depends on the peptide's primary sequence and structure (Wakankar & Borchardt, 2006).
- Oxidation. Methionine, cysteine, histidine, tryptophan and tyrosine are the residues most susceptible to oxidation. Oxidation can be triggered by contaminating oxidants, catalysed by trace metal ions, and induced by light (Li et al., 1995).
- Peptide bond cleavage, which breaks the chain (Lai & Topp, 1999).
- Dimerization and aggregation, where molecules join together (Lai & Topp, 1999).
- β-elimination and the Maillard reaction. The Maillard reaction is between amino groups and reducing sugars, so it depends on what else is in the formulation (Lai & Topp, 1999).
Some degradation products are well characterized, including diketopiperazine, pyroglutamate and succinimide formation, and oxidized residues (D'Hondt et al., 2014). Most of these change the molecule's structure, and many show up as additional peaks in an HPLC trace (see How to Read an HPLC Chromatogram).
What drives these reactions
The same review identifies the physical and chemical factors that govern solid-state reactivity: temperature, moisture content, excipients, and the physical state of the solid, meaning whether it is amorphous or crystalline (Lai & Topp, 1999). For oxidation, light and trace metals matter as well (Li et al., 1995). Two of these, temperature and moisture, are the ones a lab controls after the vial arrives.
Handling a sealed vial of lyophilized powder
These points follow from the factors above. Compound-specific storage conditions from the supplier's documentation take precedence where they exist.
- Keep it cold. Reaction rates fall with temperature, so cold storage slows every pathway above. How cold a particular peptide needs to be is compound-specific.
- Keep it dry and sealed. Moisture content is one of the main drivers of solid-state reactivity (Lai & Topp, 1999). The seal is what keeps ambient humidity out.
- Let a cold vial reach room temperature before opening it. Warm, humid air meeting a cold surface condenses, and opening a cold vial straight away invites moisture onto the powder.
- Open it as rarely as possible. Every opening lets in fresh moisture and oxygen.
- Protect it from light. Light can induce oxidation (Li et al., 1995). The original packaging or a dark container helps.
- Record dates. A COA describes a batch when it was tested. Degradation after that isn't captured on it, so the test date and your receipt date are both worth knowing (see How to Read a Peptide COA).
References
- Lai MC, Topp EM. Solid-state chemical stability of proteins and peptides. J Pharm Sci. 1999;88(5):489-500. PMID: 10229638
- Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203(1-2):1-60. PMID: 10967427
- Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490-500. PMID: 18623513
- Wakankar AA, Borchardt RT. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci. 2006;95(11):2321-36. PMID: 16960822
- D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. PMID: 25044089